Last updated: July 31, 2026
Captopril/hydrochlorothiazide is a mature, off-patent fixed-dose combination for hypertension. Its clinical development is complete, its core composition patents have expired, and no meaningful branded or biosimilar pipeline is associated with the product. Market demand persists through low-cost generic supply, but revenue potential is limited by therapeutic substitution, competition from newer fixed-dose combinations, and declining use of captopril relative to longer-acting ACE inhibitors.
What is captopril/hydrochlorothiazide used for?
Captopril/hydrochlorothiazide combines:
| Component |
Drug class |
Primary role |
| Captopril |
Angiotensin-converting enzyme inhibitor |
Reduces angiotensin II production and aldosterone activity |
| Hydrochlorothiazide |
Thiazide diuretic |
Increases sodium and water excretion |
The combination was developed for hypertension in patients who require more than one mechanism of blood-pressure control. Captopril is administered multiple times daily because of its relatively short duration of action. Hydrochlorothiazide provides complementary diuretic activity.
The branded product was marketed in the United States as Capozide by Bristol-Myers Squibb. Strengths historically included combinations such as 25/15 mg, 25/25 mg, 50/15 mg, 50/25 mg and 50/50 mg, expressed as captopril/hydrochlorothiazide. The product is now primarily a generic prescription medicine.
Captopril/hydrochlorothiazide is not a treatment for acute hypertensive emergencies. Its use is also constrained by contraindications involving pregnancy, prior ACE-inhibitor-associated angioedema, significant renal impairment in selected patients, hyperkalemia risk and clinically important drug interactions. The FDA labeling identifies fetal toxicity, angioedema, renal impairment and electrolyte disturbances as material safety concerns (U.S. Food and Drug Administration, n.d.-a).
What is the clinical-trial status of captopril/hydrochlorothiazide?
The clinical-trial program for captopril/hydrochlorothiazide is effectively closed. No late-stage development program, new indication program or modern pivotal trial is associated with the product.
Historical clinical evidence
Clinical development focused on:
- Blood-pressure reduction in mild-to-moderate hypertension
- Comparison with captopril monotherapy
- Comparison with hydrochlorothiazide monotherapy
- Dose-ranging studies
- Renal and cardiovascular effects in hypertensive populations
- Safety of combining renin-angiotensin-system inhibition with diuretic therapy
The combination was approved during the early era of ACE-inhibitor development. Its evidence base predates the current registration environment, which emphasizes ambulatory blood-pressure data, cardiovascular-outcome trials, standardized trial registries and more extensive subgroup analysis.
The clinical rationale remains pharmacologically valid. Diuretic therapy can enhance the antihypertensive effect of an ACE inhibitor, while captopril can reduce some potassium loss associated with thiazide treatment. The combination still carries independent risks of hyperkalemia, renal dysfunction, hypotension, hyponatremia and hypokalemia.
Current trial activity
ClinicalTrials.gov does not indicate a commercially relevant active development program for a new captopril/hydrochlorothiazide product or indication. Contemporary hypertension trials generally evaluate:
- Long-acting ACE inhibitor combinations
- Angiotensin receptor blocker/thiazide products
- Calcium-channel-blocker combinations
- Triple fixed-dose combinations
- SGLT2 inhibitors and mineralocorticoid receptor antagonists in cardiorenal populations
The absence of current trials reflects product maturity rather than lack of clinical utility. Generic manufacturers have no economic reason to repeat the original efficacy program unless they seek a new dosage form, a new delivery technology or a new regulatory claim.
When did captopril/hydrochlorothiazide lose exclusivity?
Core exclusivity expired decades ago. Captopril was approved by the FDA in 1981, while captopril/hydrochlorothiazide was approved during the 1980s. The principal composition-of-matter and product-development patents associated with the combination have expired.
| Milestone |
Approximate timing |
| Captopril FDA approval |
1981 |
| Original branded fixed-dose combination development |
1980s |
| Core captopril patent term expiration |
Late 1990s to early 2000s, depending on patent |
| Generic combination entry |
Established for many years |
| Current market position |
Mature generic product |
Patent-term calculations for older products vary by patent family, patent-term adjustment and regulatory extensions. Those variations do not create a current commercial exclusivity position for captopril/hydrochlorothiazide.
What patents protect captopril/hydrochlorothiazide?
No enforceable core patent estate is known to protect the standard oral captopril/hydrochlorothiazide tablet in the United States.
Historical patent scope
Historical protection generally covered:
- Captopril as an active pharmaceutical ingredient
- Processes for preparing captopril
- Pharmaceutical compositions containing captopril
- Combination therapy involving captopril and a diuretic
- Tablet formulations and manufacturing processes
The original captopril discovery was associated with Squibb, later Bristol-Myers Squibb. The principal commercial value of the patent estate ended after expiration of the underlying compound and product patents.
Formulation patents
A manufacturer could theoretically pursue a patent on:
- Modified-release captopril
- An improved stability formulation
- A novel tablet coating
- A bilayer or multilayer tablet
- A pediatric liquid formulation
- A specific particle-size distribution
- A manufacturing process with demonstrated technical advantages
Those claims would not restore exclusivity to conventional immediate-release captopril/hydrochlorothiazide tablets. Any new patent would need to satisfy novelty, non-obviousness, written-description and enablement requirements under U.S. patent law.
Manufacturing and intellectual-property barriers
Manufacturing barriers are low. Both active ingredients are established generic substances with mature supply chains. The main technical controls involve:
- Captopril oxidation and stability
- Moisture control
- Content uniformity at lower strengths
- Compatibility between active ingredients and excipients
- Dissolution performance
- Packaging against degradation
- Control of hydrochlorothiazide assay and impurities
These requirements can affect product quality and regulatory approval, but they do not create a durable barrier comparable to a protected complex biologic or specialized delivery platform.
What is the Orange Book status of captopril/hydrochlorothiazide?
The original Capozide product was approved under an FDA new drug application and is identified in historical FDA drug databases. Generic products are approved through abbreviated new drug applications demonstrating pharmaceutical equivalence and bioequivalence to the reference product, where an appropriate reference standard is designated (U.S. Food and Drug Administration, n.d.-b).
The Orange Book relevance is limited because:
- The core product patents have expired.
- The product is not protected by a current branded exclusivity period.
- Generic entry has already occurred.
- No active patent dispute is central to the market.
- Product availability varies by manufacturer, strength and wholesaler inventory.
The absence of current enforceable patents means a new generic applicant would generally face an abbreviated approval pathway rather than a patent-driven Paragraph IV litigation risk.
Which companies are challenging the captopril/hydrochlorothiazide product?
The principal competitive activity is generic supply, not branded patent litigation. Generic hypertension manufacturers that have historically marketed captopril, hydrochlorothiazide or related combination products include large U.S. and international suppliers such as Mylan, Teva, Sandoz, Lupin, Zydus and other regional manufacturers. Product availability changes over time as companies discontinue low-volume strengths or adjust portfolios.
No major current Paragraph IV campaign is associated with the conventional captopril/hydrochlorothiazide tablet. A new abbreviated new drug application would be more likely to enter an already open market than to trigger high-value litigation.
What litigation and settlement agreements affect the product?
No material ongoing U.S. patent litigation or commercial settlement agreement is known to control generic entry for conventional captopril/hydrochlorothiazide.
Historical disputes involving captopril centered on compound patents, process patents and generic competition during the product’s original commercial life. Those disputes no longer determine market access for ordinary tablets. Litigation risk could arise if a company introduced a novel formulation or made a narrow method-of-use claim, but that would concern the new product rather than the legacy combination.
Does captopril/hydrochlorothiazide face biosimilar risk?
No. Captopril/hydrochlorothiazide is a synthetic small-molecule drug, not a biologic. It is subject to generic-drug competition under the abbreviated new drug application pathway, not biosimilar competition under the Public Health Service Act.
The relevant competitive risks are:
- Additional ANDA approvals
- Manufacturer discontinuations
- Wholesale price competition
- Substitution to other ACE inhibitor combinations
- Substitution to ARB/thiazide products
- Clinical migration to once-daily therapies
How does captopril/hydrochlorothiazide compare with competing combinations?
Captopril/hydrochlorothiazide has lower commercial momentum than newer fixed-dose combinations.
| Combination |
Commercial advantage |
Commercial limitation |
| Captopril/hydrochlorothiazide |
Low cost; established efficacy; familiar ACE inhibitor mechanism |
Short captopril duration; multiple daily dosing; mature generic pricing |
| Lisinopril/hydrochlorothiazide |
Once-daily use; broad prescribing familiarity |
Also exposed to generic price erosion |
| Enalapril/hydrochlorothiazide |
Long clinical history; established generic availability |
Less commonly prioritized than newer combinations |
| Losartan/hydrochlorothiazide |
Avoids some ACE-inhibitor cough; strong hypertension adoption |
Usually higher unit cost than older ACE inhibitor combinations |
| Valsartan/hydrochlorothiazide |
Once-daily dosing and broad clinical use |
Generic competition and supply variability |
| Amlodipine/benazepril |
Strong combination of calcium-channel blockade and ACE inhibition |
More complex safety and tolerability profile |
The strongest commercial substitutes are lisinopril/hydrochlorothiazide and ARB/thiazide combinations. Prescribers often favor longer-acting agents because once-daily dosing can improve adherence.
What is the market outlook for captopril/hydrochlorothiazide?
The product has a stable but declining-value market profile. Volume demand is supported by the global prevalence of hypertension, while revenue is constrained by generic pricing and substitution.
Market drivers
- Continued global hypertension prevalence
- Low acquisition cost
- Established clinical familiarity
- Availability in multiple strengths
- Use in price-sensitive health systems
- Continued need for combination therapy
Market restraints
- Short captopril half-life
- Multiple-dose schedules
- Increased use of once-daily ACE inhibitors and ARBs
- Greater availability of single-pill combinations
- Low manufacturer margins
- Periodic discontinuation of low-volume strengths
- Safety monitoring requirements involving renal function and electrolytes
Revenue projection
Public company filings generally do not report captopril/hydrochlorothiazide revenue separately. The product is usually included within broader generic cardiovascular portfolios. A drug-specific global revenue forecast therefore has limited analytical value because transaction prices differ sharply by country and because product availability is fragmented across manufacturers.
A reasonable commercial projection is:
| Period |
Expected market direction |
Rationale |
| 2024-2026 |
Stable to modest decline |
Persistent demand but continued generic price pressure |
| 2027-2029 |
Low-single-digit annual revenue decline |
Therapeutic substitution and manufacturer rationalization |
| 2030 onward |
Mature residual market |
Continued use in low-cost channels and selected regional markets |
Volume is likely to decline more slowly than revenue. The combination can remain clinically relevant while becoming less attractive as a standalone commercial asset.
What generic launch scenarios exist?
Scenario 1: Additional conventional generic entry
This is the most likely scenario. A manufacturer could enter with an immediate-release tablet after demonstrating bioequivalence and meeting chemistry, manufacturing and controls requirements. The commercial outcome would probably be rapid price competition.
Scenario 2: Portfolio consolidation
Manufacturers may reduce the number of marketed strengths or discontinue the product where demand does not support manufacturing and distribution costs. This can create temporary shortages without creating patent-based market power.
Scenario 3: Reformulated product
A modified-release or improved-stability formulation could obtain separate approval and potentially patent protection. Commercial success would depend on a clear adherence, tolerability or pharmacokinetic advantage. A reformulation would compete against inexpensive established tablets and would face a high reimbursement hurdle.
Scenario 4: Regional expansion
The strongest remaining opportunity is likely in markets where low-cost combination therapy is prioritized and generic penetration is incomplete. Regulatory requirements, local pricing controls and procurement tenders would determine returns.
What geographic markets offer the greatest opportunity?
The United States is a low-growth market for the product because of deep generic penetration and extensive substitution. Western Europe has similar characteristics, with national reimbursement systems favoring low-cost medicines.
Potentially better volume opportunities exist in:
- South Asia
- Southeast Asia
- Latin America
- Middle-income markets with expanding hypertension diagnosis
- Public-sector procurement markets
Local opportunities depend on registration status, manufacturing economics, tender access and distribution reliability. The product’s low price limits the value of premium commercialization strategies.
How strong is the patent estate for captopril/hydrochlorothiazide?
The patent estate is weak for conventional products and has no meaningful blocking position in the United States. Its strengths are historical rather than current.
| Estate category |
Current strength |
| Captopril compound patents |
Expired |
| Hydrochlorothiazide compound patents |
Expired |
| Conventional combination patents |
Expired or commercially nonblocking |
| Standard tablet formulation |
Low protection |
| Manufacturing know-how |
Moderate operational value, weak exclusionary value |
| Novel delivery system |
Potentially protectable if technically differentiated |
| Method-of-use claims |
Limited value for established hypertension use |
Key Takeaways
- Captopril/hydrochlorothiazide is a mature generic antihypertensive combination.
- Its major clinical trials were conducted during the original development period; no meaningful modern development program is active.
- Core patents and exclusivity have expired.
- Conventional tablets face no material current Paragraph IV or biosimilar risk.
- Generic manufacturing barriers are manageable and primarily involve stability, dissolution and quality control.
- Revenue is expected to decline gradually because of generic price erosion and substitution to once-daily combinations.
- The most credible commercial opportunities are low-cost regional supply, public procurement and a technically differentiated reformulation.
- The main competitive products are lisinopril/hydrochlorothiazide and ARB/thiazide combinations.
FAQs
Is captopril/hydrochlorothiazide still FDA approved?
Captopril/hydrochlorothiazide has an established FDA approval history, and generic versions have been approved through the ANDA pathway. Current marketing status varies by product, manufacturer and strength.
Can a company file a Paragraph IV certification for captopril/hydrochlorothiazide?
A company can make the applicable patent certifications in an ANDA, but conventional captopril/hydrochlorothiazide products do not face a meaningful active-patent barrier in the U.S. market.
Is captopril/hydrochlorothiazide once daily?
The combination is not generally favored for once-daily use because captopril is relatively short acting. Prescribing frequency depends on the product strength, patient response and labeling.
Could a new captopril/hydrochlorothiazide formulation receive patent protection?
Yes. A genuinely novel formulation, delivery system or manufacturing process could be patentable. Protection would apply to the claimed innovation, not to the old immediate-release combination itself.
Is captopril/hydrochlorothiazide commercially attractive for licensing?
The legacy product has limited licensing value because it is generic and price constrained. A licensing opportunity would be more credible for a differentiated formulation, regional registration package, manufacturing platform or supply agreement.
References
-
U.S. Food and Drug Administration. (n.d.-a). Captopril and hydrochlorothiazide prescribing information. FDA labeling database.
-
U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
-
U.S. Food and Drug Administration. (n.d.-c). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
National Library of Medicine. (n.d.). ClinicalTrials.gov. https://clinicaltrials.gov/
-
Whelton, P. K., Carey, R. M., Aronow, W. S., et al. (2018). 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension, 71(6), e13-e115. https://doi.org/10.1161/HYP.0000000000000065
-
World Health Organization. (2021). Guideline for the pharmacological treatment of hypertension in adults. World Health Organization.
